Company Summary: Guided Therapeutics, Inc.

Business Focus

• Guided Therapeutics, Inc. is a medical technology company specializing in developing and commercializing innovative medical devices aimed at improving healthcare.

Core Product

• The primary product is the LuViva® Advanced Cervical Scan, a non-invasive, painless device for detecting cervical cancers and precancers.
• Technology utilized: biophotonics—uses light reflection and fluorescence analysis to detect structural and biochemical changes associated with cervical cancer.
• Designed for use at the point of care: scans the cervix, analyzes reflected/fluorescent light, and provides rapid results without pain.

Key Applications

• Developing world: as a primary screening tool for cervical cancer where traditional infrastructure (Pap tests) is limited, expensive, or lacks skilled personnel.
• Developed world: as a triage device to follow traditional Pap or HPV testing; reduces unnecessary follow-up procedures caused by false positives.

Market & Regulatory Status

• Significant international demand, especially in developing countries.
• Executed distribution agreements in over 40 countries.
• Regulatory approvals obtained in Europe (CE Mark), Canada (Health Canada), Mexico (COFEPRIS), Kenya, India, with active pursuits for FDA approval in the U.S.
• Currently, 148 LuViva devices sold globally (as of December 31, 2024).
• Approximately 78,950 single-use cervical guides sold to international distributors.

Customers & Revenue

• Revenue primarily from the sale of LuViva devices and disposables.
• In 2024, revenue was approximately $6,940.
• In 2023, revenue was approximately $97,706.
• Anticipates future sales of about $1.5 million in the next year based on current purchase orders.
• Orders from distributors in Turkey and Indonesia, with expected sales of 22-26 devices in 2025.
• Main distributors include SMI in China and NTI in Eastern Europe and Russia.

Employees & Staff

• As of December 31, 2024:
  • 4 salaried employees
  • 3 consultants providing full- or part-time services

Financial Highlights & Income

• 2024 Net Loss: approximately $2.6 million.
• 2023 Net Loss: approximately $3.76 million.
• Accumulated deficit at December 31, 2024: $153.7 million.
• No net income or profitability as of the date.
• The company operates at a financial loss, with a negative working capital of about $5 million.
• Has not paid dividends and has no plans to in the foreseeable future.
• The company has a limited cash reserves—about $388,000 as of December 31, 2024.

Development & Regulatory Progress

• Conducting a U.S. clinical trial involving around 400 women; about 320 enrolled as of March 1, 2025.
• Working with Chinese authorities through SMI for NMPA approval; application filed in October 2024, review ongoing, possibly approval in second quarter of 2025.
• When approved, will market in Europe, China, India, Middle East, and other regions.
• The U.S. FDA approval process ongoing; current status involves clinical trial and submission of data for PMA approval.

Strategic & Operational Notes

• Focused on large-scale commercialization of LuViva.
• Engaged in research on early detection of other cancers, such as esophageal and skin cancers, but primary commercial efforts are on cervical cancer.
• Reliance on distributors for international sales; main channels include China, Eastern Europe, and Southeast Asia.
• Manufacturing involves outsourcing to third-party facilities in Hungary and China, with licensing agreements for manufacturing rights in China.
• The company faces ongoing regulatory, commercialization, and fundraising challenges due to being early-stage with limited revenue, ongoing losses, and the need for FDA approval.

In summary: Guided Therapeutics, Inc. develops biophotonics-based medical devices, predominantly the LuViva cervical cancer detection device, targeting global markets especially in developing countries, with ongoing efforts to gain FDA approval for expanded use. Its revenues are limited, and it operates at a significant net loss with a small employee base, focusing heavily on regulatory approval, sales growth through international distributors, and expanding potential cancer detection applications.